Table 1 Demographic and clinical data of 51 cases.
Characteristics | Data |
|---|---|
Gender (male/female) | 29/22 |
Age (years) | 34.68 ± 10.68 Range:18–62 |
Course of disease (months) | 45.26 ± 60.64 Range:0.5–360 |
CDAI | 240.73 ± 73.88 |
Laboratory examination | |
CRP (mg/L) | 31.87 ± 39.86 |
ESR (mm/h) | 38.37 ± 28.88 |
Symptom (n, %) | |
Abdominal pain | 28 (54.9%) |
Diarrhea | 17 (33.3%) |
Bloody stools | 9 (17.6%) |
Shapeless stool | 4 (7.8%) |
Fever | 4 (7.8%) |
Intestinal obstruction | 6 (11.8%) |
perianal abscess and anal fistula | 8 (15.7%) |
Epigastric discomfort | 1 (2.0%) |
Constipation | 1 (2.0%) |
Findings of CT/MRI (n, %) | |
Thickening and enhancement of the bowel wall | 33 (64.7%) |
Perforations, fistulas and sinus | 5 (9.8%) |
Stricture | 8 (15.7%) |
“Comb pattern” of mesenteric angiogenesis | 2 (3.9%) |
Iliopsoas abscess | 1 (2%) |
Obstruction | 2 (3.9%) |
Therapeutic method (n, %) | |
Mesalazine | 6 (23.6%) |
Mesalazine after antituberculosis therapy | 6 (11.8%) |
Hormones and immunosuppressants | 17 (33.3%) |
Infliximab | 9 (17.6%) |
Surgical treatment | 13 (25.5%) |
